The surfactants

American Journal of Perinatology

Volumn 17, Issue 7, 2000, Pages 335-343

  Kallapur, S ^a   Ikegami, M ^a  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

Author keywords

Respiratory distress syndrome; Surfactant treatment; Ventilatory styles

Indexed keywords

PHOSPHATIDYLETHANOLAMINE; PHOSPHATIDYLGLYCEROL; PHOSPHATIDYLINOSITOL; PHOSPHOLIPID; SPHINGOMYELIN; SURFACTANT;

BLOOD OXYGENATION; BOLUS INJECTION; BREATHING; DRUG METABOLISM; INFANT MORTALITY; LUNG ALVEOLUS; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY DISTRESS SYNDROME; REVIEW;

ANIMALS; ANIMALS, NEWBORN; HUMANS; INFANT, NEWBORN; LUNG; PULMONARY SURFACTANTS; RESPIRATION; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, NEWBORN;

EID: 0034529337     PISSN: 07351631     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2000-13445     Document Type: Review

References (73)

1. Surface properties in relation to atelectasis and hyaline membrane disease
2. Improved ventilation of prematurely delivered primates following tracheal deposition of surfactant
3. Lung expansion in the premature rabbit fetus after tracheal deposition of surfactant
4. Effect of tracheal deposition of surfactant on air expansion of lungs: Study on premature rabbit fetuses
5. The alveolar lining of the premature newborn rabbit after pharyngeal deposition of surfactant
6. Artificial surfactant therapy in hyaline membrane disease
7. The influence of the wider use of surfactant therapy on neonatal mortality among blacks and whites
8. A population study: Mortality and morbidity after availability of surfactant therapy. Newborn Lung Project
9. Decreasing mortality associated with the introduction of surfactant therapy: An observational study of neonates weighing 601 to 1300 grams at birth
10. Trend in mortality from respiratory distress syndrome in the United States. 1970-1995
11. Molecular structures and interactions of pulmonary surfactant components
12. Isolated lamellar bodies from rat lung: Correlated ultrastructural and biochemical studies
13. Ultrastructure of tubular myelin and lamellar bodies in fast-frozen adult rat lung
14. Immunomodulatory functions of surfactant
15. Surfactant protein-A enhances respiratory syncytial virus clearance in vivo
16. Surfactant protein A-deficient mice are susceptible to group B streptococcal infection
17. Surfactant protein-A-deficient mice are susceptible to Pseudomonas aeruginosa infection
18. Normal surfactant pool sizes and inhibition-resistant surfactant from mice that overexpress surfactant protein A
19. Altered surfactant homeostasis and alveolar type II cell morphology in mice lacking surfactant protein D
20. Surfactant protein-D regulates surfactant phospholipid homeostasis in vivo
21. Spontaneous emphysema in SP-D targeted mice
22. Targeted disruption of the surfactant protein B gene disrupts surfactant homeostasis, causing respiratory failure in newborn mice
23. Aberrant processing of surfactant protein C in hereditary SP-B deficiency
24. A mutation in the surfactant protein B gene responsible for fatal neonatal respiratory disease in multiple kindreds
25. Different ventilation strategies alter surfactant responses in pre-term rabbits
26. Pulmonary surfactant therapy
27. Appropriate surfactant usage in 1996
28. Mechanisms initiating lung injury in the preterm
29. Pulmonary hemorrhage and exogenous surfactant therapy: A meta-analysis
30. A comparison of surfactant as immediate prophylaxis and as rescue therapy in newborns of less than 30 weeks' gestation
31. Comparison of prophylaxis and rescue treatment with Curosurf in neonates less than 30 weeks' gestation: A randomized trial
32. Prophylactic administration of calf lung surfactant extract is more effective than early treatment of respiratory distress syndrome in neonates of 29 through 32 weeks' gestation
33. Porcine surfactant replacement therapy in newborns of 25-31 weeks' gestation: A randomized, multicentre trial of prophylaxis versus rescue with multiple low doses
34. Randomized, placebo-controlled trial of human surfactant given at birth versus rescue administration in very low birth weight infants with lung immaturity
35. Bovine surfactant replacement therapy in neonates of less than 30 weeks' gestation: A randomized controlled trial of prophylaxis versus treatment
36. Surfactant treatment of the very preterm infant
37. Early versus delayed neonatal administration of a synthetic surfactant The judgment of OSIRIS Open study of infants at high risk of or with respiratory insufficiency: The role of surfactant
38. Surfactant therapy and nasal continuous positive airway pressure for newborns with respiratory distress syndrome
39. Nasal continuous positive airway pressure and early surfactant therapy for respiratory distress syndrome in newborns of less than 30 weeks' gestation
40. Surfactant for the treatment of respiratory distress syndrome
41. Lung phospholipids of human fetuses and infants with and without hyaline membrane disease
42. Effect of surfactant substitution on lung effluent phospholipids in respiratory distrss syndrome: Evaluation of surfactant phospholipid turnover, pool size, and the relationship to severity of respiratory failure
43. Surfactant release in excised rat lung is stimulated by air inflation
44. The effect of epinephrine on tracheal fluid flow and surfactant efflux in fetal sheep
45. Surfactant phosphatidylcholine metabolism and surfactant function in preterm, ventilated lambs
46. Surfactant metabolism in surfactant-treated preterm ventilated lambs
47. Surfactant metabolism
48. Single- versus multiple-dose surfactant replacement therapy in neonates of 30 to 36 weeks' gestation with respiratory distress syndrome
49. Distribution of surfactant and ventilation in surfactant-treated preterm lambs
50. Ultrasonic nebulized in comparison with instilled surfactant treatment of preterm lambs
51. Surfactant nebulization versus instillation during high frequency ventilation in surfactant-deficient rabbits
52. Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury
53. Bronchoalveolar lavage with KL4-surfactant in models of meconium aspiration syndrome
54. A protein that inhibits surfactant in respiratory distress syndrome
55. Changes in exogenous surfactant in ventilated preterm lamb lungs
56. Tidal volume effects on surfactant treatment responses with the initiation of ventilation in preterm lambs
57. Lung injury and surfactant metabolism following hyperventilation of premature lambs
58. In vitro conversion of surfactant subtypes is altered in alveolar surfactant isolated from injured lungs
59. Positive end-expiratory pressure preserves surfactant function in preterm lambs
60. Optimizing alveolar expansion prolongs the effectiveness of exogenous surfactant therpy in the adult rabbit
61. Early nasal continuous positive airway pressure treatment reduces the need for intubation in very low birth weight infants
62. Initial treatment of preterm infants: Continuous positive airway pressure or ventilation?
63. Delivery room management of extremely low birth weight infants: Spontaneous breathing or intubation?
64. Effects of ventilation style on surfactant metabolism and treatment response in preterm lambs
65. Prospective randomized comparison of high-frequency oscillatory and conventional ventilation in respiratory distress syndrome
66. The Provo multicenter early high-frequency oscillatory ventilation trial: Improved pulmonary and clinical out come in respiratory distress syndrome
67. High-frequency oscillatory ventilation compared with conventional mechanical ventilation in the treatment of respiratory failure in preterm infants
68. A prospective, randomized, multicenter trial of highfrequency oscillatory ventilation compared with conventional ventilation in preterm infants with respiratory distress syndrome receiving surfactant
69. Prospective randomized multicenter comparison of highfrequency oscillatory ventilation (HFOV) and conventional ventilation (CV) in preterm infants <30 weeks' gestational age (GA) with RDS
70. Effects of rSP-C surfactant on oxygenation and histology in a ratlung-lavage model of acute lung injury
71. Bronchopulmonary segmental lavage with surfaxin (KL-4) surfactant for acute respiratory distress syndrome (ARDS)
72. Bronchoalveolar lavage with dilute surfaxin (KL-4 surfactant) for the management of the meconium aspiration syndrome (MAS)